MREO: Class Action Filed—Act Now to Protect Your Investment!

Class Action Lawsuit – What Happened?

A securities class action lawsuit has been filed on behalf of Mereo BioPharma (NASDAQ: MREO) investors who bought the stock between June 5, 2023 and December 26, 2025 (www.globenewswire.com). The lawsuit alleges that Mereo “provided false and misleading information” about the anticipated success of its Phase 3 trials for setrusumab, an experimental osteoporosis drug for osteogenesis imperfecta (OI) (intellectia.ai). Specifically, executives expressed confidence that setrusumab would reduce fracture rates and touted the program’s prospects, while allegedly concealing adverse facts – namely, that neither of the Phase 3 ORBIT or COSMIC studies met their primary endpoints (www.globenewswire.com) (www.globenewswire.com). When the truth emerged on December 29, 2025, Mereo’s stock price collapsed from $2.31 to $0.29 in a single day – an 87.7% plunge (www.globenewswire.com). Law firms like Rosen Law are urging investors to apply for lead plaintiff status by April 6, 2026 to preserve their rights (intellectia.ai). This legal action underscores the severity of the recent setback and the importance of protecting shareholder interests amid possible corporate missteps.

Company Overview – Rare Disease Focus with Setbacks

Mereo BioPharma Group plc is a UK-based clinical-stage biopharmaceutical company focused on rare diseases (www.mereobiopharma.com). Its lead programs included setrusumab (UX143) for treating osteogenesis imperfecta and alvelestat for alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD) (www.mereobiopharma.com). Until recently, setrusumab was the flagship asset, developed in partnership with Ultragenyx Pharma. Mereo also has a pipeline of other assets, such as vantictumab (licensed to a partner for a rare bone disease) and two oncology candidates (etigilimab and navicixizumab) which have been partnered or are inactive (www.mereobiopharma.com) (www.mereobiopharma.com). The company’s strategy has been to advance these candidates through late-stage trials, often in collaboration with larger partners, given the high costs of rare-disease drug development.

The December 2025 trial failure was a major blow. On Dec. 29, Mereo announced that the Phase 3 ORBIT and COSMIC studies for setrusumab did not achieve statistical significance on their primary endpoint – reduction in annualized fracture rate – compared to placebo or standard of care (www.otcmarkets.com). This was despite showing significant improvement in bone mineral density (a secondary endpoint), and a trend toward fewer fractures in the youngest patient group that was not statistically significant (www.otcmarkets.com). The news devastated investor confidence because setrusumab was expected to be a transformative therapy for OI and a key value driver. Mereo’s management is now conducting further analyses and considering discussions with regulators to determine if any path forward remains for setrusumab (www.otcmarkets.com). However, the trial failure raises serious questions about the program’s viability and about management’s prior optimistic statements. It also shifts the spotlight to alvelestat – now the company’s leading hope – and whether Mereo can secure a partner to initiate Phase 3 trials in AATD-LD (www.otcmarkets.com). In short, Mereo is a one-time high-flyer in rare diseases that is now in damage-control mode after the OI setback.

Dividend Policy & Shareholder Yield

Mereo is not a dividend-paying company, which is typical for clinical-stage biotechs. According to its SEC filings, “Mereo has never paid or declared any cash dividends…and does not anticipate paying any cash dividends” on its shares (www.sec.gov). All available capital is reinvested into R&D and operating expenses to advance the drug pipeline rather than being returned to shareholders. Consequently, MREO’s dividend yield is 0%, and investors’ return prospects are tied entirely to stock price appreciation (or depreciation) rather than income. In essence, shareholders are betting on clinical and commercial success of Mereo’s drug candidates, not on receiving any near-term cash distributions.

(Note: Metrics like AFFO/FFO – commonly used for cash-generative real estate or infrastructure companies – are not applicable here, as Mereo has no recurring operating cash flows or profits to distribute. The company’s “funds from operations” are negative given its developmental stage.)

Financial Position and Leverage

Despite its recent turmoil, Mereo entered 2026 with a solid cash cushion relative to its size. As of December 31, 2025, the company had approximately $41 million in cash and equivalents (www.otcmarkets.com). Management has implemented cost cuts (scaling back pre-commercial and manufacturing spend after the setrusumab data) and now guides that this cash runway is sufficient to fund operations into mid-2027 under current plans (www.otcmarkets.com). This extends prior guidance (which had projected funding “into 2027” before the trial failure) by reducing expenses related to the halted OI program. The existing cash should cover currently committed trials, operating costs and capex for roughly 1.5 years from now (www.otcmarkets.com), assuming no major new initiatives are started without partner funding.

Leverage: Mereo has operated primarily through equity financing and collaboration payments, with only minimal debt. It does not carry traditional bank loans and had no significant long-term debt as of the latest reports. Historically, the company issued convertible loan notes to raise capital – for example, a £3.8 million unsecured convertible note issued to Novartis in 2020 (convertible at £0.265 per share) (www.sec.gov). This note’s maturity was extended to February 10, 2025, with interest paid up to the extension date (www.sec.gov). In fact, Mereo raised a substantial portion of its funding through such offerings: in 2020–2021 it raised about $183 million via share/ADS sales and convertible debt, and also received a $50 million upfront payment from Ultragenyx for the setrusumab partnership (www.sec.gov). These financings greatly bolstered its balance sheet. Over time, many of the convertible notes have converted into equity. As of year-end 2022, only about £6.2 million of the 2020–2021 notes remained outstanding (www.sec.gov), and that remainder either converted or came due by early 2025. With the Feb 2025 note maturity now passed, Mereo likely has no material debt outstanding (any residual would have been very small).

Maturities: The company’s most notable obligations had been those convertible notes. The Novartis note due Feb 2025 was the key maturity – presumably now resolved via conversion to shares or payoff. Mereo had previously also maintained a credit facility, but it repaid that bank debt in full in 2020 (www.sec.gov) to eliminate interest costs. Therefore, at present Mereo’s capital structure is predominantly equity. This conservative balance sheet means credit risk is low – there are no looming debt repayments that could pressure liquidity. It also means dilution risk has been the primary way the company finances itself (issuing new shares when needed). Indeed, total shares outstanding have increased over time (nearly 800 million ordinary shares as of Q3 2025, or ~159 million ADS after accounting for 5:1 ADS ratio (www.mereobiopharma.com)), reflecting past equity raises and note conversions. Existing shareholders have been diluted, but the trade-off is that Mereo has cash to operate and very little leverage.

Coverage and Liquidity

With effectively no interest-bearing debt, traditional interest coverage ratios are a non-issue – there is negligible interest expense to “cover” with earnings. The more pertinent question is cash burn coverage: can Mereo cover its ongoing R&D and overhead costs with its cash reserves? For now, the answer appears to be yes, in the medium term. The company’s quarterly net losses in 2024–2025 ranged roughly from $7–15 million (www.mereobiopharma.com) (www.mereobiopharma.com), depending on R&D activity, and full-year 2024 net loss was $43.3 million (up from $29.5M in 2023 due to ramped trial and pre-launch spending) (www.mauritiusbusinessreview.com). At that burn rate, the ~$41 million cash on hand will be drawn down over the next several quarters. However, management’s cost-cutting measures should reduce the burn. In fact, by Q3 2025 the quarterly loss had narrowed to $7.0 million, half the level a year prior (www.mereobiopharma.com), thanks in part to winding down less critical programs.

Mereo projects that its cash is sufficient through mid-2027, which suggests around 18+ months of runway from the start of 2026 (www.otcmarkets.com). This indicates an annual cash burn in the ~$20–25 million range going forward (significantly lower than 2024’s spending). The extended runway is partly due to management “reductions and delays in pre-commercial and manufacturing activities” after the setrusumab trial failure (www.otcmarkets.com). In other words, they scaled back expenses related to an anticipated drug launch that is now on hold, thus preserving cash. If these assumptions hold, Mereo should not require near-term financing to sustain basic operations. Importantly, this guidance excludes any new revenue or upfront cash that could come if Mereo secures a partnership deal for alvelestat or monetizes non-core assets (www.mereobiopharma.com) (www.mereobiopharma.com). Any such deal (e.g. an upfront payment from a pharma partner) could further extend the runway.

From a liquidity standpoint, Mereo’s current ratio is healthy – it has tens of millions in cash versus only single-digit millions in typical current liabilities (like payables and accruals) (www.mereobiopharma.com). The company also qualifies for annual R&D tax credits (especially in the UK), which have provided some cash inflow historically (e.g. ~$1–2M receivables each year) (www.mereobiopharma.com) (www.mereobiopharma.com). This helps offset a small portion of expenses. Overall, short-term liquidity is not a red-flag issue at present: Mereo can cover its obligations and planned spending for the next year or two without new capital. The bigger concern is long-term funding if its pipeline progresses or if timelines extend – for example, launching a new Phase 3 trial or commercial launch would eventually require more capital or a partnership infusion. Investors should monitor Mereo’s quarterly cash burn and any updates to the runway guidance as the company adapts its strategy post-setback.

Valuation and Stock Performance

Mereo’s stock has been severely punished by the market in light of recent events. The share price (ADS) hovers around $0.40–$0.50 in March 2026 (uk.finance.yahoo.com), down nearly 80% from its 2025 highs. The dramatic decline came after the failure of setrusumab’s Phase 3 trials was announced: the stock lost almost 88% of its value in one day (Dec 29, 2025) (www.globenewswire.com) and has only partially rebounded off the absolute lows. At ~$0.50 per ADS, Mereo’s market capitalization is roughly $75–80 million (with ~159 million ADS equivalent shares outstanding (www.mereobiopharma.com)). This valuation is only slightly higher than the company’s last reported cash ($41M) – implying an enterprise value on the order of ~$35–40 million. In other words, the market is currently assigning a very modest value to Mereo’s entire pipeline and intangible assets, likely reflecting deep skepticism after the OI trial failure. Essentially, the stock is trading near “cash value”, a level often seen in biotechs that have suffered a major R&D setback and where future prospects are uncertain.

Traditional valuation multiples like P/E or EV/EBITDA are not meaningful, since Mereo has no earnings and is operating at a loss. Similarly, metrics like P/FFO (price to funds-from-operations) don’t apply – Mereo’s “FFO” is negative given it has no steady revenues. A more relevant metric for context is price-to-book (P/B) value. Mereo’s book value (shareholders’ equity) at year-end 2024 was about $50–55 million (mostly cash) (www.mereobiopharma.com) (www.mereobiopharma.com). Even after the 2025 loss, book equity likely remains in the range of $35–40 million, so the current P/B is roughly 2x. However, one should note that book value is comprised of cash and some intangibles; the market clearly doubts the intangibles (pipeline) have much immediate value, thus the low EV relative to cash.

Analysts’ views have adjusted but haven’t completely given up on MREO. According to recent analyst consensus, there is still a majority “Buy” rating bias (6 Buys, 2 Holds, 0 Sell as per one survey) (intellectia.ai). Price targets, however, have been slashed after the trial failure. For example, Cantor Fitzgerald cut its target from $6 to $3 on Dec 29, 2025 (intellectia.ai) (intellectia.ai), reflecting lowered expectations but still implying significant upside from the current sub-$1 price if the company can recover. The average target price across covering analysts was around $2.00–$2.50 in early 2026 (intellectia.ai), which suggests the street sees potential value in alvelestat or other assets that could justify a higher stock price than today’s levels. That said, given the stock’s penny-stock status and volatility, many of these targets are highly speculative. Investors should be aware that MREO shares could face Nasdaq compliance issues if the price remains below $1 – often companies in this situation consider a reverse stock split to regain compliance if the price doesn’t organically recover. No such action has been announced yet, but it’s an overhang to consider if the stock languishes at these levels in the coming months.

In summary, MREO’s current valuation reflects a company on the ropes: it’s priced only slightly above liquidation value, with the market taking a “wait and see” approach on whether management can extract any value from the pipeline (through partnerships or improved trial data) post-setback. This low valuation could present upside if the company executes well from here – but it also signals the high risk investors perceive at the moment.

Key Risks and Red Flags

Pipeline Risk & Concentration: Mereo’s fortunes are now tied largely to a single remaining major program, alvelestat. The failure of setrusumab’s trials leaves a big hole – not only in the pipeline, but in the company’s credibility. If alvelestat fails to secure a partner or show strong Phase 3 results down the line, Mereo would have little else to fall back on. The company does have a few other shots on goal (e.g. the partnered vantictumab program for osteopetrosis, and out-licensed oncology assets), but those are earlier-stage or out of Mereo’s direct control (www.mereobiopharma.com) (www.mereobiopharma.com). Essentially, pipeline diversification is limited, which heightens the impact of any single program’s success or failure. After one major failure, the margin for error is thin.

Clinical and Regulatory Uncertainty: Even though setrusumab improved bone density in OI patients, it did not reduce fractures significantly – which is what regulators care about (www.otcmarkets.com). The road to approval for that drug is now highly uncertain. Mereo and Ultragenyx are analyzing the data to see if any subset or approach could salvage it (www.otcmarkets.com), but the hurdles are high. Regulators typically require clear fracture reduction to approve an OI therapy, given bisphosphonates already improve bone density without proven fracture reduction in OI (www.otcmarkets.com). There’s a risk that setrusumab could be abandoned entirely, which would formally write off years of work and partnership milestones (Ultragenyx’s collaboration had up to $245M in milestone payments contingent on success, which now appear out of reach (www.mereobiopharma.com) (www.mereobiopharma.com)). As for alvelestat in AATD-LD, while it has shown promise in Phase 2 and has orphan/Fast Track designations (www.mereobiopharma.com), Phase 3 has yet to begin. The design and endpoints have been aligned with FDA/EMA guidance (www.mereobiopharma.com), but until a study is underway and data is seen (likely years out), its efficacy remains unproven. The regulatory pathway for rare disease drugs can be complex, and there is no guarantee that alvelestat’s Phase 3 (once it happens) will meet endpoints or that a partner will fund it to completion. In short, clinical risk remains very high for Mereo’s assets.

Dependence on Partners: Mereo’s business model heavily relies on partnerships for funding and support of clinical programs. Ultragenyx led (and paid for) the OI trials, and presumably an eventual alvelestat Phase 3 would be financed by a partner. This reliance introduces counterparty risk: a partner might decide to terminate a collaboration if results disappoint or strategic priorities change. For instance, Ultragenyx’s commitment to OI is now in question given the outcome – they have their own shareholders and may cut losses. If Ultragenyx pulls back, Mereo alone cannot easily finance a new trial of setrusumab. Similarly, Mereo has been “continuing to advance partnering discussions” for alvelestat (www.mereobiopharma.com) (www.mereobiopharma.com), but there’s no certainty of a deal on favorable terms. Any delay in finding a partner could stall the program. Mereo even warns that it relies on third parties to conduct and fund trials – a risk factor noted in its SEC filings (www.otcmarkets.com). Thus, the company’s progress is not entirely in its own hands. This reliance can slow down development timelines and leaves Mereo vulnerable if potential partners are hesitant (especially after seeing what happened with setrusumab).

Shareholder Dilution & Financing Risk: Although Mereo has enough cash for now, eventually it may need more capital (if, for example, it decides to co-fund a trial or if cash burn is higher than expected). Given the low stock price, any new equity raise at current levels would be highly dilutive to existing shareholders. This creates a catch-22: the stock is low because of uncertainty, but raising new funds to extend runway or start new projects could further depress the share price. The company does have an at-the-market (ATM) facility available (as many small caps do), meaning it could sell small amounts of stock periodically. But doing so at <$1 per share is not ideal. There’s also listing risk: should the stock trade below $1 for an extended period, Nasdaq could issue a deficiency notice. Mereo would then have a period (typically 180 days) to get the share price back above $1, or else consider a reverse stock split. While management hasn’t commented on this yet, it’s a risk factor that current and potential investors must bear in mind given the sub-$1 trading range.

Legal and Reputation Risk: The class action lawsuit itself is a red flag pertaining to corporate transparency and governance. Plaintiffs allege that Mereo’s executives “disseminated false or misleading statements and concealed material adverse facts” about the OI trials (www.globenewswire.com). If this allegation gains traction, it suggests management may have been overly promotional or even negligent in their communications. Even if Mereo ultimately settles the case (as many companies do, via D&O insurance coverage), the episode may damage management’s credibility with investors. It could also distract leadership and incur legal costs. Additionally, the lawsuit brings unwelcome attention at a time when Mereo is trying to rebuild trust. Investors will recall that Mereo had activist shareholder disputes in the past (in 2022, an activist investor pressured the company for changes). Now with a class action, the corporate governance spotlight is on Mereo again. Any perception of ongoing governance issues or shareholder-unfriendly behavior will keep the stock depressed. From a financial standpoint, the direct impact of the lawsuit might be limited to legal fees or an eventual settlement (which typically would be covered mostly by insurance). But the indirect impact – on reputation, on management focus, and on investor sentiment – is a key risk. New investors may hesitate to get involved until this cloud is resolved.

Macro Environment: It’s worth noting that the biotech sector in general has been challenged in recent years. Rising interest rates and risk-off sentiment have made investors less forgiving of unprofitable biotech companies. Financing is harder to come by in this climate except for those with very strong data. Mereo, being a cash-burning micro-cap with a recent trial failure, faces an uphill battle in attracting new capital or a lucrative partnership. This external environment is a risk factor beyond Mereo’s control. If market conditions worsen or if biotech sentiment remains weak, Mereo’s stock could languish regardless of company-specific progress.

In summary, Mereo exhibits elevated risk on multiple fronts: clinical (pipeline uncertainty), strategic (need for partners), financial (potential dilution), and governance (lawsuit and past activism). These risks have manifested in the stock’s deep decline and will continue to overhang the company until key questions are answered.

Outlook – Questions to Watch Going Forward

Despite the challenges, Mereo is not without options. Here are the key open questions and catalysts that will determine whether the stock can recover or if further pain is ahead:

– Can setrusumab be salvaged in any form? Management and Ultragenyx are conducting additional analyses of the ORBIT and COSMIC data (www.otcmarkets.com). They will be looking for subgroups or secondary endpoints that might convince regulators to consider some limited approval or to justify another trial. One hint from the data: in the youngest OI patients (in the COSMIC study, ages 2–<7), there was a decreased fracture rate trend correlated with improved bone density, though not statistically significant (www.otcmarkets.com). It’s possible that with a larger sample or longer follow-up, significance could be reached. Will regulators allow an approach using bone mineral density (BMD) as a surrogate endpoint for OI? Historically, fracture reduction is required, but if no therapy exists, regulators might be flexible if BMD gains are very robust. Mereo has indicated it may seek regulatory advice on this (www.otcmarkets.com) (www.otcmarkets.com). The outcome of those discussions (likely to be known later in 2026) will determine if setrusumab is dead or has a path (perhaps requiring a new trial or a narrower indication). If the program is scrapped, Mereo might also recoup some costs by selling or out-licensing any intellectual property (though expectations would be low in that scenario). Investors should watch for any announcements on setrusumab’s fate – this will affect whether Ultragenyx’s collaboration continues or ends, and whether any of those potential milestones could ever materialize (currently the market is pricing in zero chance).

– Will Mereo secure a partner for alvelestat, and when? Alvelestat for AATD-LD is now the crown jewel of the pipeline. It has shown encouraging Phase 2 results (improvements in certain biomarkers and lung function decline slowdown, according to prior trial readouts), and has orphan drug status in both the US and EU (www.mereobiopharma.com). Importantly, Mereo has done the groundwork with regulators on what a Phase 3 needs to demonstrate (www.mereobiopharma.com). However, Mereo likely cannot fund a global Phase 3 on its own – it will need a larger pharma or biotech partner to step in. Management has been in partnering discussions for some time (www.mereobiopharma.com), and previously guided they hoped to initiate Phase 3 with a partner by end of 2024 (www.mereobiopharma.com) (www.mereobiopharma.com). That timetable slipped, presumably because negotiations are ongoing or potential partners waited to see the setrusumab outcome (and now may drive a harder bargain). A key catalyst would be a partnership announcement for alvelestat. This could involve an upfront payment (injecting new cash into Mereo), and the partner taking on trial costs in exchange for rights to commercialize in certain territories. The size of any upfront and the caliber of the partner will be telling: a strong deal could restore confidence and validate alvelestat’s value; a lukewarm or low-dollar deal might signal that the asset isn’t highly sought after. If no deal comes, Mereo faces a choice later this year or next – either attempt a smaller Phase 3 on its own (likely not feasible financially) or shelve alvelestat as well. In essence, the clock is ticking to find a partner. Keep an eye on industry conferences (e.g. the European Respiratory Society meeting, or JPM Healthcare Conference updates) where such deals might be unveiled.

– How will the class action resolve? The lead plaintiff selection will occur by April 2026, after which the legal process will move forward. These cases often take months or years to resolve, often ending in a settlement. For shareholders, the direct financial impact on Mereo might be limited if insurance covers the payout, but any ugly revelations during the case could further harm the stock. Conversely, a quick dismissal of the case or a modest settlement could remove this overhang. It will be important to monitor if multiple law firms* pile on with similar suits (several have already announced investigations (www.ktmc.com) (rosenlegal.com)), or if any regulatory agencies launch inquiries. So far, it is a civil matter. The reputation of management is at stake – how they respond (transparency, willingness to improve disclosure) could influence investor sentiment. Mereo’s board will also need to reassure investors that proper controls are in place to prevent overly optimistic or misleading communications in the future.

– Will there be strategic changes (management or M&A)? When a biotech loses ~90% of its value, sometimes changes follow. CEO Dr. Denise Scots-Knight has led Mereo since its founding; she navigated past challenges (including the 2022 proxy fight) and remained at the helm. Now would be a time when some companies might shake up leadership or the board to signal a fresh start. There’s no concrete indication of that yet, but it’s worth watching if any key executives depart or if activist investors re-emerge pushing for changes. Additionally, given Mereo’s low valuation, it could become a takeover target or a candidate for merger. Larger pharma companies could be interested in alvelestat or even in using Mereo as a vehicle to reverse-merge other assets (a common outcome for struggling biotechs with cash). Mereo’s cash on hand and Nasdaq listing have value in and of themselves; a cash-rich shell with a listing can be attractive for private companies looking to go public via merger. Management has not indicated any intent to pursue M&A, but investors should remain open to the possibility. Sometimes, if the standalone prospects dim, a merger or sale of the company might maximize whatever value is left for shareholders. Any rumors or indications along these lines could cause volatility in the stock.

– Can management rebuild trust and refocus the narrative? Finally, a more subjective but crucial question: will Mereo’s leadership restore confidence? The next few public communications (quarterly updates, conference presentations) need to show a clear plan and honest assessment of the challenges. Investors will be looking for signs that management is not “in denial” about the setback, but rather pivoting effectively. For instance, management has already adjusted spending to preserve cash (www.otcmarkets.com) – a prudent move. They also continue to highlight the unmet need in OI and AATD, which is valid – these are diseases with no approved therapies in the US (www.otcmarkets.com) (www.otcmarkets.com). If Mereo can articulate a feasible path forward (even if it’s just one lead program) and maybe achieve a small win (like a partnership or positive interim data in another study), it may begin to regain lost credibility. This is more of a qualitative, long-term factor, but it will influence whether the stock remains a distressed penny stock or can gradually recover as a legitimate rare-disease play.

In conclusion, Mereo’s story is at a crossroads. The class action urges investors to “act now to protect your investment,” which in legal terms means joining the lawsuit (intellectia.ai). From an investment perspective, “acting to protect your investment” in MREO also means staying informed and vigilant about these upcoming developments. There is potential value left in Mereo – the company still has cash, a remaining Phase 3–ready asset, and a Nasdaq listing – but realizing that value will depend on deft execution in the coming quarters. Investors should weigh the high risks (as outlined above) against the possibility of a turnaround. Until clearer answers emerge on the lawsuit outcome, partnership prospects, and any pipeline progress, MREO remains a speculative investment. Cautious investors may prefer to wait on the sidelines for now, while those who continue to hold or are considering entry should do so with eyes wide open and a close watch on the news flow. In the volatile world of biotech, fortunes can eventually recover – but as Mereo has shown, they can also deteriorate rapidly if expectations are not met. Proceed accordingly, and stay tuned for the next chapter in this unfolding situation.

Sources: Key information was drawn from Mereo’s SEC filings and investor communications, including the latest financial results and the January 2026 corporate update (www.otcmarkets.com) (www.mereobiopharma.com). Details of the class action allegations and timeline are sourced from official law firm announcements and press releases (www.globenewswire.com) (intellectia.ai). All financial figures and investor data are as reported by the company or reputable financial media (www.mauritiusbusinessreview.com) (intellectia.ai). These source citations are provided inline throughout this report for reference.

For informational purposes only; not investment advice.